EX-23.1 5 tm2114556d11_ex23-1.htm EXHIBIT 23.1


Exhibit 23.1


Consent of Independent Registered Public Accounting Firm


We consent to the use of our report dated May 6, 2021, except for the reverse stock split described in Note 1, which is as of June 22, 2021, with respect to the financial statements of Aerovate Therapeutics, Inc., included herein and to the reference to our firm under the heading “Experts” in the prospectus. Our report dated May 6, 2021 contains an explanatory paragraph that states that the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.




San Diego, California

June 24, 2021